Search
Search
About
Log in
Join
Experiences with
Ofatumumab
Posts
Communities
57 public posts
Filter results
Reassessment of Anti-CD20 Therapy in Lymphoid Malignancies: Impact, Limitations, and New Directions (Rituximab, Ofatumumab and Obinutuzumab)
Two of these agents,
ofatumumab
and obinutuzumab, have been approved for use in certain clinical settings. Research comparing these newer antibodies with rituximab is ongoing.
Two of these agents,
ofatumumab
and obinutuzumab, have been approved for use in certain clinical settings. Research comparing these newer antibodies with rituximab is ongoing.
AussieNeil
Partner
in
CLL Support
7 years ago
I've just reviewed treatments and am more confused!
- acalabrutinib is less toxic and 2nd-generation but availability is uncertain - other "TGR-1202 (PI3K inhibitors)" are in the pipeline (I've noted idelalisib, duvelisib and
ofatumumab
but have no idea what these do, how effective they may be, or what the long-term effects are because they're so new.
- acalabrutinib is less toxic and 2nd-generation but availability is uncertain - other "TGR-1202 (PI3K inhibitors)" are in the pipeline (I've noted idelalisib, duvelisib and
ofatumumab
but have no idea what these do, how effective they may be, or what the long-term effects are because they're so new.
deveritt
in
CLL Support
7 years ago
inPractice Oncology CLL resource updated
Key additions include: * Availability of an online decision aid for CLL * Updated guidance on the expanded use of ibrutinib in frontline treatment of CLL * New indication and updated guidance on the use of
ofatumumab
as extended therapy for patients with relapsed or refractory CLL * New approval
Key additions include: * Availability of an online decision aid for CLL * Updated guidance on the expanded use of ibrutinib in frontline treatment of CLL * New indication and updated guidance on the use of
ofatumumab
as extended therapy for patients with relapsed or refractory CLL * New approval
AussieNeil
Partner
in
CLL Support
8 years ago
Want to take advantage of all our features? Just log in!
Log in
or
Join
Dr Susan O'Brien Sheds Light on Role of Next-Generation Agents in CLL
[/i] OncLive interview with Dr O'Brien: http://global.onclive.com/web-exclusives/expert-sheds-light-on-role-of-nextgeneration-agents-in-cll Drugs mentioned: ibrutinib (Imbruvica) idelalisib (Zydelig) duvelisib in trial versus
ofatumumab
(Arzerra) TGR-1202 (PI3K inhibitor) acalabrutinib, (ACP-196) a
[/i] OncLive interview with Dr O'Brien: http://global.onclive.com/web-exclusives/expert-sheds-light-on-role-of-nextgeneration-agents-in-cll Drugs mentioned: ibrutinib (Imbruvica) idelalisib (Zydelig) duvelisib in trial versus
ofatumumab
(Arzerra) TGR-1202 (PI3K inhibitor) acalabrutinib, (ACP-196) a
AussieNeil
Partner
in
CLL Support
8 years ago
Integrating Emerging Evidence Into the Management of CLL Patients; what leading CLL experts recommend in 4 case studies
Treatment options covered include:
Bendamustine and Rituximab (BR) Chlorambucil + CD20 monoclonal Antibody (mAb) Chlorambucil ±
Ofatumumab
Fludarabine, Cyclophosphamide, and Rituximab (FCR) Ibrutinib (BTK inhibitor) Idelalisib (PI3K inhibitor) and Rituximab Lenalidomide Obinutuzumab and Chlorambucil
Treatment options covered include:
Bendamustine and Rituximab (BR) Chlorambucil + CD20 monoclonal Antibody (mAb) Chlorambucil ±
Ofatumumab
Fludarabine, Cyclophosphamide, and Rituximab (FCR) Ibrutinib (BTK inhibitor) Idelalisib (PI3K inhibitor) and Rituximab Lenalidomide Obinutuzumab and Chlorambucil
AussieNeil
Partner
in
CLL Support
9 years ago
InPractice CLL reference update - Idelalisib+Ofatumumab for relapsed/refractory patients. (Another CLL reference worth bookmarking)
The comprehensive InPractice reference for diagnosing, monitoring and treating CLL is regularly updated, with the latest update incorporating the addition of
ofatumumab
to idelalisib in patients with relapsed/refractory CLL plus the initial results from HELIOS trial of ibrutinib added to BR.
The comprehensive InPractice reference for diagnosing, monitoring and treating CLL is regularly updated, with the latest update incorporating the addition of
ofatumumab
to idelalisib in patients with relapsed/refractory CLL plus the initial results from HELIOS trial of ibrutinib added to BR.
AussieNeil
Partner
in
CLL Support
9 years ago
Explainer: what are biologics and biosimilars?
explainer-what-are-biologics-and-biosimilars-45308 Thomas Morrow, MD and Linda Hull Felcone explain how biologics differ from chemically derived drugs in ways that affect their cost, production, administration and clinical efficacy here: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564302/
Obinutuzumab,
explainer-what-are-biologics-and-biosimilars-45308 Thomas Morrow, MD and Linda Hull Felcone explain how biologics differ from chemically derived drugs in ways that affect their cost, production, administration and clinical efficacy here: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3564302/
Obinutuzumab,
AussieNeil
Partner
in
CLL Support
9 years ago
Latest news on the COMPLEMENT 2 trial, duvelisib (IPI-145), TGR-1202 and a novel SYK inhibitor TAK-659 presented at EHA and ICML
Here's a few CLL related updates on the COMPLEMENT 2 trial -
ofatumumab
with fludarabine and cyclophosphamide (OFC), the PI3Kδ/γ inhibitor duvelisib (IPI-145), TGR-1202 a next-generation PI3kδ and a novel SYK (Spleen tYrosine Kinase) inhibitor TAK-659, from Hematology Times (free membership).
Here's a few CLL related updates on the COMPLEMENT 2 trial -
ofatumumab
with fludarabine and cyclophosphamide (OFC), the PI3Kδ/γ inhibitor duvelisib (IPI-145), TGR-1202 a next-generation PI3kδ and a novel SYK (Spleen tYrosine Kinase) inhibitor TAK-659, from Hematology Times (free membership).
AussieNeil
Partner
in
CLL Support
9 years ago
Living with CLL
He was put on the Rialto Trial (
Ofatumumab
/ Bendamustine plus Idelalisib or placebo. and is now half way through treatment. Has anyone else got experience of this trial or know someone who has ?
He was put on the Rialto Trial (
Ofatumumab
/ Bendamustine plus Idelalisib or placebo. and is now half way through treatment. Has anyone else got experience of this trial or know someone who has ?
TrishaG
in
CLL Support
9 years ago
UK - NICE Guidance for NHS use of Ofatumumab in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia -
If you have chronic lymphocytic leukaemia, and your doctor thinks that
ofatumumab
with chlorambucil is the right treatment, you should be able to have the treatment on the NHS.
Ofatumumab
(with chlorambucil) should be available on the NHS within 3 months of the guidance being issued.
If you have chronic lymphocytic leukaemia, and your doctor thinks that
ofatumumab
with chlorambucil is the right treatment, you should be able to have the treatment on the NHS.
Ofatumumab
(with chlorambucil) should be available on the NHS within 3 months of the guidance being issued.
HAIRBEAR_UK
Administrator
in
CLL Support
9 years ago
UK - NICE Guidance for NHS England & Wales use of obinutuzumab in combination with chlorambucil for untreated chronic lymphocytic leukaemia
[/i] the other bus arrived with guidance [TA344]
Ofatumumab
in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia https://healthunlocked.com/cllsupport/posts/131890843/nice-guidance-for-nhs-use-of-
ofatumumab
-in-combination-with-chlorambucil-or-bendamustine-for-untreated-chronic-lymphocytic-leukaemia
[/i] the other bus arrived with guidance [TA344]
Ofatumumab
in combination with chlorambucil or bendamustine for untreated chronic lymphocytic leukaemia https://healthunlocked.com/cllsupport/posts/131890843/nice-guidance-for-nhs-use-of-
ofatumumab
-in-combination-with-chlorambucil-or-bendamustine-for-untreated-chronic-lymphocytic-leukaemia
HAIRBEAR_UK
Administrator
in
CLL Support
9 years ago
Ofatumumab (Arzerra®) is accepted for restricted use within NHS Scotland.
Ofatumumab
(Arzerra) [i]
Advice
following a full submission assessed under the orphan process
ofatumumab
(Arzerra®) is accepted for restricted use within NHS Scotland.
Ofatumumab
(Arzerra) [i]
Advice
following a full submission assessed under the orphan process
ofatumumab
(Arzerra®) is accepted for restricted use within NHS Scotland.
HAIRBEAR_UK
Administrator
in
CLL Support
9 years ago
Chemo makes resistant cancer stem cells???
et_cid=4472513&et_rid=741277821&type=cta The research involves breast cancer and the resistance is referred to as from "chemotherapy" so I wonder if the finding of resistance would be applicable to all therapies i.e. immunotherapies (CD20 mAbs like Rituxan,
Ofatumumab
, Obinutuzumab etc), Kinase inhibitors
et_cid=4472513&et_rid=741277821&type=cta The research involves breast cancer and the resistance is referred to as from "chemotherapy" so I wonder if the finding of resistance would be applicable to all therapies i.e. immunotherapies (CD20 mAbs like Rituxan,
Ofatumumab
, Obinutuzumab etc), Kinase inhibitors
ThreeWs
in
CLL Support
9 years ago
Arzerra (ofatumumab) PBS listed in Australia
[i]ARZERRA (
ofatumumab
) in combination with chlorambucil will be listed on the Pharmaceutical Benefits Scheme as of 01 Apr 2015 for patients with CLL [u]who have not received prior therapy and are inappropriate for fludarabine-based therapy[/u], GlaxoSmithKline has said.
[i]ARZERRA (
ofatumumab
) in combination with chlorambucil will be listed on the Pharmaceutical Benefits Scheme as of 01 Apr 2015 for patients with CLL [u]who have not received prior therapy and are inappropriate for fludarabine-based therapy[/u], GlaxoSmithKline has said.
AussieNeil
Partner
in
CLL Support
9 years ago
New Treatment!
I finished a round of Chemotherapy (
Ofatumumab
/Bendamustine) in January 2013 and since then have just got weaker as my blood count rose. I saw my consultant yesterday and I am to start IBRUTINIB/IMBRUVICA within the next two to three weeks.
I finished a round of Chemotherapy (
Ofatumumab
/Bendamustine) in January 2013 and since then have just got weaker as my blood count rose. I saw my consultant yesterday and I am to start IBRUTINIB/IMBRUVICA within the next two to three weeks.
john133
in
CLL Support
9 years ago
ASCO 2014: Dr. Byrd: What we could only Learn from a CLL Phase 3 Trial about Ibrutinib and Ofatumumab in Relapsed CLL
It is full of important issues concerning trial design and equipoise, and surprising findings in the Resonate trial comparing
ofatumumab
to ibrutinib Enjoy but please do forgive my lousy recording technique- Dr. Byrd is very clear and what he has to say is worthwhile.
It is full of important issues concerning trial design and equipoise, and surprising findings in the Resonate trial comparing
ofatumumab
to ibrutinib Enjoy but please do forgive my lousy recording technique- Dr. Byrd is very clear and what he has to say is worthwhile.
bkoffman
CLL CURE Hero
in
CLL Support
10 years ago
A bit confused
I have had six months of Chemotherapy which was two days a month of BENDAMUSTINE/
OFATUMUMAB
I finished the Chemo in January this year when my blood count went down from 150 to 15 .
I have had six months of Chemotherapy which was two days a month of BENDAMUSTINE/
OFATUMUMAB
I finished the Chemo in January this year when my blood count went down from 150 to 15 .
john133
in
CLL Support
10 years ago
Richters update
It could be just the cll in which case they could hold off treatment for a while as my blood work is good and within 'normal range' (wbc 4, hb 12.5, platelets 157), however it could be the richters has returned (I finished CHOP in jan 2013 and the maintenance period of
ofatumumab
in november 2013 for
It could be just the cll in which case they could hold off treatment for a while as my blood work is good and within 'normal range' (wbc 4, hb 12.5, platelets 157), however it could be the richters has returned (I finished CHOP in jan 2013 and the maintenance period of
ofatumumab
in november 2013 for
norahmaria
in
CLL Support
10 years ago
I'm looking for CLL patients who are on ofatumumab and what their reactions have been.
judithpetersen
in
CLL Support
10 years ago
Ofatumumab and leg pains ?
Hi everyone. I finished 12 months maintainence period of ofatamumab in november 2013 and since then have been experiencing very bad aching pains in my legs and feet, also calf cramps at night. Has a yone else experienced the same ?
Hi everyone. I finished 12 months maintainence period of ofatamumab in november 2013 and since then have been experiencing very bad aching pains in my legs and feet, also calf cramps at night. Has a yone else experienced the same ?
norahmaria
in
CLL Support
10 years ago
1
2
3
Next page
Filter results
Clear filters
Posted in
All communities
CLL Support
50 results
My MSAA Community
6 results
British Tinnitus Association
1 result
Sort by
Most Relevant
Newest